Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27682250 | 0.83 | EGFR (0.44) | EGFRKDM4EACHEERN1MAPT | |
| 1-Naphthol SCHEMBL27616902 | 0.78 | EGFR (0.67) | EGFRKDM4EMAPKAPK2ACHEMAPT | |
| SCHEMBL4036487 | 0.75 | EGFR (0.47) | EGFRKDM4EMAPTGAARAB9A | |
| SCHEMBL2007641 | 0.75 | EGFR (0.47) | EGFRKDM4ETDP1ALDH1A1PI4KA | |
| SCHEMBL29618252 | 0.75 | EGFR (0.47) | EGFRKDM4EMAPTCYP1A2HPGD | |
| SCHEMBL1261572 | 0.75 | EGFR (0.47) | EGFRKDM4EMAPTCYP1A2HPGD | |
| SCHEMBL19716355 | 0.75 | EGFR (0.47) | EGFRKDM4EPI4KAPI4K2BPI4K2A | |
| SCHEMBL277181 | 0.75 | EGFR (0.47) | EGFRKDM4EPI4KAPI4K2BPI4K2A | |
| SCHEMBL3820499 | 0.75 | EGFR (0.47) | EGFRMAPTCYP1A2TSHRALDH1A1 | |
| SCHEMBL1502533 | 0.75 | EGFR (0.47) | EGFRPI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 156 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9821067-B2 | Lipopeptides for delivery of nucleic acids | MARINA BIOTECH, INC. (US) | 2017-11-21 | — | — | US | claimed |
| WO-2016154694-A1 | N-ACYLHYDRAZONE COMPOUNDS INHIBITING HISTONE DESACETYLASE ENZYMES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PRODUCING SAME | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO-UFRJ (BR) | 2016-10-06 | — | — | WO | claimed |
| US-9220785-B2 | Lipopeptides for delivery of nucleic acids | MARINA BIOTECH, INC. (US) | 2015-12-29 | — | — | US | claimed |
| CN-104672311-A | Lipopeptides for delivery of nucleic acids | MARINA BIOTECH INC | 2015-06-03 | — | — | CN | claimed |
| US-20130231382-A1 | LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS | MARINA BIOTECH, INC. (US) | 2013-09-05 | — | — | US | claimed |
| CN-101939027-A | Lipopeptides for delivery of nucleic acids | MDRNA INC | 2011-01-05 | — | — | CN | claimed |
| US-20100240731-A1 | LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS | MDRNA, INC. (US) | 2010-09-23 | — | — | US | claimed |
| CN-101674853-A | Amino acid lipids and uses thereof | NASTECH PHARM CO | 2010-03-17 | — | — | CN | claimed |
| US-20080317839-A1 | AMINO ACID LIPIDS AND USES THEREOF | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-12-25 | — | — | US | claimed |
| EP-1282680-A1 | COMPOSITIONS COMPRISING CYCLODEXTRIN | THE PROCTER & GAMBLE COMPANY (US) | 2003-02-12 | — | — | EP | claimed |
| US-6503413-B2 | Polyalkylene polysiloxane, buffering agent, aqueous carrier | THE PROCTER & GAMBLE COMPANY | 2003-01-07 | — | — | US | claimed |
| EP-1255806-A1 | STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| US-20020011584-A1 | Stable, aqueous compositions for treating surfaces, especially fabrics | THE PROCTOR & GAMBLE COMPANY | 2002-01-31 | — | — | US | claimed |
| US-20020010154-A1 | Compositions comprising cyclodextrin | THE PROCTER & GAMBLE COMPANY | 2002-01-24 | — | — | US | claimed |
| WO-2001088076-A1 | COMPOSITIONS COMPRISING CYCLODEXTRIN | THE PROCTER & GAMBLE COMPANY (US) | 2001-11-22 | — | — | WO | claimed |
| US-6289286-B1 | Surface regeneration of biosensors and characterization of biomolecules associated therewith | BIACORE AB (SE) | 2001-09-11 | — | — | US | claimed |
| WO-2001060961-A1 | STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS | THE PROCTER & GAMBLE COMPANY (US) | 2001-08-23 | — | — | WO | claimed |
| EP-1082607-A1 | SURFACE REGENERATION OF BIOSENSORS | Biacore AB (SE) | 2001-03-14 | — | — | EP | claimed |
| WO-1999063333-A1 | SURFACE REGENERATION OF BIOSENSORS | BIACORE AB (SE) | 1999-12-09 | — | — | WO | claimed |
| US-20260102395-A1 | INHIBITING HISTONE DEACETYLASE 6 | EIKONIZO THERAPEUTICS, INC. (US) | 2026-04-16 | — | — | US | disclosed |
| US-12590084-B2 | Oxadiazole HDAC6 inhibitors and uses thereof | EIKONIZO THERAPEUTICS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20260055090-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2026-02-26 | — | — | US | disclosed |
| US-20250250263-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | EIKONIZO THERAPEUTICS, INC. (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250230166-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| CN-119451678-A | Inhibition of histone deacetylase 6 (HDAC 6) | 艾科尼佐治疗股份有限公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4504191-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | Eikonizo Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-4504190-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | Eikonizo Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| CN-119212707-A | Oxadiazole HDAC6 inhibitors and uses thereof | 艾科尼佐治疗股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-3252172-B1 | FAST HYBRIDIZATION FOR NEXT GENERATION SEQUENCING TARGET ENRICHMENT | AGILENT TECHNOLOGIES INC (US) | 2024-09-11 | — | — | EP | disclosed |
| WO-2023196605-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196605-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-112939995-A | Process for preparing dioxanoquinazoline derivatives | 北京工业大学 | 2021-06-11 | — | — | CN | disclosed |
| CN-111217821-B | Preparation method of series dioxane quinazoline derivatives | 北京工业大学 | 2021-04-23 | — | — | CN | disclosed |
| CN-111217821-A | Preparation method of series dioxane quinazoline derivatives | 北京工业大学 | 2020-06-02 | — | — | CN | disclosed |
| CN-105051018-B | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | 爱尔兰詹森科学公司 | 2019-09-20 | — | — | CN | disclosed |
| EP-3456845-A1 | FAST HYBRIDIZATION FOR NEXT GENERATION SEQUENCING TARGET ENRICHMENT | Agilent Technologies, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| EP-3441480-A1 | FAST HYBRIDIZATION FOR NEXT GENERATION SEQUENCING TARGET ENRICHMENT | Agilent Technologies, Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| US-10093962-B2 | Fast hybridization for next generation sequencing target enrichment | AGILENT TECHNOLOGIES, INC. (US) | 2018-10-09 | — | — | US | disclosed |
| EP-3252172-A2 | FAST HYBRIDIZATION FOR NEXT GENERATION SEQUENCING TARGET ENRICHMENT | Agilent Technologies, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-9821067-B2 | Lipopeptides for delivery of nucleic acids | MARINA BIOTECH, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-9587268-B2 | Fast hybridization for next generation sequencing target enrichment | AGILENT TECHNOLOGIES INC. (US) | 2017-03-07 | — | — | US | disclosed |
| WO-2016154694-A1 | N-ACYLHYDRAZONE COMPOUNDS INHIBITING HISTONE DESACETYLASE ENZYMES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHOD FOR PRODUCING SAME | UNIVERSIDADE FEDERAL DO RIO DE JANEIRO-UFRJ (BR) | 2016-10-06 | — | — | WO | disclosed |
| US-9339461-B2 | Arginine-based lipids for delivery of therapeutics | MARINA BIOTECH, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20160058870-A1 | LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS | MARINA BIOTECH INC (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160017405-A1 | FAST HYBRIDIZATION FOR NEXT GENERATION SEQUENCING TARGET ENRICHMENT | AGILENT TECHNOLOGIES, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-9220785-B2 | Lipopeptides for delivery of nucleic acids | MARINA BIOTECH, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9115341-B2 | Method for expanding hematopoietic stem cells using heterocyclic compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2015-08-25 | — | — | US | disclosed |
| EP-2902504-A1 | Fast hybridization for next generation sequencing target enrichment | Agilent Technologies, Inc. (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150211047-A1 | FAST HYBRIDIZATION FOR NEXT GENERATION SEQUENCING TARGET ENRICHMENT | AGILENT TECHNOLOGIES, INC. (US) | 2015-07-30 | — | — | US | disclosed |
| CN-104805180-A | Fast hybridization for next generation sequencing target enrichment | AGILENT TECHNOLOGIES INC | 2015-07-29 | — | — | CN | disclosed |
| EP-1636192-B9 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2015-07-01 | — | — | EP | disclosed |
| CN-104382853-A | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MARINA BIOTECH INC | 2015-03-04 | — | — | CN | disclosed |
| US-8877729-B2 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| CN-102231979-B | Liposome efficient delivery methods and compositions for gene silencing therapeutics | MARINA BIOTECH, INC. (US) | 2014-10-29 | — | — | CN | disclosed |
| US-20140308304-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. | 2014-10-16 | — | — | US | disclosed |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2014-02-20 | — | — | US | disclosed |
| US-20140037714-A1 | AMINO ACID LIPIDS AND USES THEREOF | MARINA BIOTECH, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| EP-1636192-B1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL IND LTD (JP) | 2014-01-15 | — | — | EP | disclosed |
| US-8552031-B2 | 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| US-8501824-B2 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| WO-2013086373-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| US-8440666-B2 | Pyridazinone compounds and P2X7 receptor inhibitors | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| CN-101674853-B | Amino acid lipids and uses thereof | NASTECH PHARM CO | 2013-03-27 | — | — | CN | disclosed |
| US-20130039970-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MARINA BIOTECH, INC. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2013-01-10 | — | — | US | disclosed |
| US-8318796-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-11-27 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8093251-B2 | Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| CN-102231979-A | Liposome efficient delivery methods and compositions for gene silencing therapeutics | MDRNA INC | 2011-11-02 | — | — | CN | disclosed |
| US-8026368-B2 | Hydrazide compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2011-09-27 | — | — | US | disclosed |
| US-20110177160-A1 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| US-20110130327-A1 | Multi-Arm Amines and Uses Thereof | MARINA BIOTECH, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7939505-B2 | Amino acid lipids and uses thereof | MARINA BIOTECH, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| US-20100310537-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100310536-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100310535-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100298559-A1 | OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES LIMITED | 2010-11-11 | — | — | US | disclosed |
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | HENNEQUIN LAURENT FRANCOIS ANDRE | 2010-11-04 | — | — | US | disclosed |
| EP-2233561-A1 | METHOD FOR AMPLIFICATION OF HEMATOPOIETIC STEM CELL USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| EP-2233468-A1 | OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST | Nissan Chemical Industries, Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| EP-2228435-A1 | METHOD FOR AMPLIFICATION OF HEMATOPOIETIC STEM CELL USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-15 | — | — | EP | disclosed |
| EP-2228434-A1 | AMPLIFICATION METHOD FOR HEMATOPOIETIC STEM CELLS WITH HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-15 | — | — | EP | disclosed |
| EP-2203429-A1 | PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS | Nissan Chemical Industries, Ltd. (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | MDRNA, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7696214-B2 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2010-04-13 | — | — | US | disclosed |
| CN-101674853-A | Amino acid lipids and uses thereof | NASTECH PHARM CO | 2010-03-17 | — | — | CN | disclosed |
| US-7618777-B2 | Composition and method for array hybridization | AGILENT TECHNOLOGIES, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20090281317-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-7595415-B2 | α-Substituted vinyltin compound | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-09-29 | — | — | US | disclosed |
| US-7576115-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-18 | — | — | US | disclosed |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| WO-2009057827-A1 | PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-07 | — | — | WO | disclosed |
| EP-2025671-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| US-20090023939-A1 | ALPHA-SUBSTITUTED VINYLTIN COMPOUND | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20080317839-A1 | AMINO ACID LIPIDS AND USES THEREOF | NASTECH PHARMACEUTICAL COMPANY INC. (US) | 2008-12-25 | — | — | US | disclosed |
| US-20080207960-A1 | Methods, compositions, and kits for post-hybridization processing of arrays | AGILENT TECHNOLOGIES, INC. | 2008-08-28 | — | — | US | disclosed |
| EP-1947101-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
| US-7351841-B2 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2008-01-31 | — | — | US | disclosed |
| CN-100345844-C | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2007-10-31 | — | — | CN | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
| CN-101035784-A | New bicyclic antibiotics | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-12 | — | — | CN | disclosed |
| EP-1282680-B1 | COMPOSITIONS COMPRISING CYCLODEXTRIN | PROCTER & GAMBLE (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1819692-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2007-08-22 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-7160891-B2 | Quinazoline derivatives for the treatment of T cell mediated diseases | ASTRAZENECA AB (SE) | 2007-01-09 | — | — | US | disclosed |
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB | 2006-11-16 | — | — | US | disclosed |
| EP-1255806-B1 | STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS | PROCTER & GAMBLE (US) | 2006-09-27 | — | — | EP | disclosed |
| US-20060210997-A1 | Composition and method for array hybridization | AGILENT TECHNOLOGIES, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1702990-A1 | Composition and method for array hybridization | Agilent Technologies, Inc. (US) | 2006-09-20 | — | — | EP | disclosed |
| CN-1798739-A | 3-alkylidenehydrazino substituted heteroaryl compounds as thrombopoietin receptor activators | NISSAN CHEMICAL IND LTD (JP) | 2006-07-05 | — | — | CN | disclosed |
| WO-2006062240-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2006-06-15 | — | — | WO | disclosed |
| US-7049438-B2 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2006-05-23 | — | — | US | disclosed |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NISSAN CHEMICAL INDUSTRIES LIMITED (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1764651-A | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2006-04-26 | — | — | CN | disclosed |
| EP-1636192-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | Nissan Chemical Industries, Ltd. (JP) | 2006-03-22 | — | — | EP | disclosed |
| EP-1450808-B8 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| EP-1450808-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-06-15 | — | — | EP | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | ASTRAZENECA AB (SE) | 2005-02-17 | — | — | US | disclosed |
| WO-2004108683-A1 | 3-ALKYLIDENEHYDRAZINO SUBSTITUTED HETEROARYL COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | ASTRAZENECA AB (SE) | 2004-10-28 | — | — | US | disclosed |
| EP-1450808-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | Astrazeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| EP-1292594-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| CN-1434821-A | Quinazoline derivatives for the treatment of tumours | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
| WO-2003045395-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF T CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2001094341-A9 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2003-04-17 | — | — | WO | disclosed |
| EP-1292594-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | AstraZeneca AB (SE) | 2003-03-19 | — | — | EP | disclosed |
| EP-1282680-A1 | COMPOSITIONS COMPRISING CYCLODEXTRIN | THE PROCTER & GAMBLE COMPANY (US) | 2003-02-12 | — | — | EP | disclosed |
| US-6503413-B2 | Polyalkylene polysiloxane, buffering agent, aqueous carrier | THE PROCTER & GAMBLE COMPANY | 2003-01-07 | — | — | US | disclosed |
| EP-1255806-A1 | STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS | THE PROCTER & GAMBLE COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020011584-A1 | Stable, aqueous compositions for treating surfaces, especially fabrics | THE PROCTOR & GAMBLE COMPANY | 2002-01-31 | — | — | US | disclosed |
| US-20020010154-A1 | Compositions comprising cyclodextrin | THE PROCTER & GAMBLE COMPANY | 2002-01-24 | — | — | US | disclosed |
| WO-2001094341-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | ASTRAZENECA AB (SE) | 2001-12-13 | — | — | WO | disclosed |
| WO-2001088076-A1 | COMPOSITIONS COMPRISING CYCLODEXTRIN | THE PROCTER & GAMBLE COMPANY (US) | 2001-11-22 | — | — | WO | disclosed |
| US-6289286-B1 | Surface regeneration of biosensors and characterization of biomolecules associated therewith | BIACORE AB (SE) | 2001-09-11 | — | — | US | disclosed |
| WO-2001060961-A1 | STABLE, AQUEOUS COMPOSITIONS FOR TREATING SURFACES, ESPECIALLY FABRICS | THE PROCTER & GAMBLE COMPANY (US) | 2001-08-23 | — | — | WO | disclosed |
| EP-1082607-A1 | SURFACE REGENERATION OF BIOSENSORS | Biacore AB (SE) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999063333-A1 | SURFACE REGENERATION OF BIOSENSORS | BIACORE AB (SE) | 1999-12-09 | — | — | WO | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0491814-A1 | TETRACYCLIC IMIDAZOQUINAZOLINE DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS. | NOVO NORDISK AS (DK) | 1992-07-01 | — | — | EP | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| WO-1991003478-A1 | TETRACYCLIC IMIDAZOQUINAZOLINE DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS | NOVO NORDISK A/S (DK) | 1991-03-21 | — | — | WO | disclosed |
| WO-1991003478-A1 | TETRACYCLIC IMIDAZOQUINAZOLINE DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS | NOVO NORDISK A/S (DK) | 1991-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (40 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322747-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | EGFR 3354/4885KDM4E 2674/4885MAPKAPK2 1161/4885 |
| US-20130231382-A1 | LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS | LNPEP, LPXN, SLC27A1 | EGFR 1882/4885KDM4E 4784/4885MAPKAPK2 4127/4885 |
| US-20110077290-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | EGFR 242/4885KDM4E 4480/4885MAPKAPK2 2152/4885 |
| US-20060094694-A1 | Heterocyclic compounds and thrombopoietin receptor activators | NR2C2, ROR1, NR0B2 | EGFR 213/4885KDM4E 4422/4885MAPKAPK2 2105/4885 |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | EGFR 4/4885KDM4E 2435/4885MAPKAPK2 640/4885 |
| US-20060210997-A1 | Composition and method for array hybridization | CDC73, DDHD2, TP53 | EGFR 2073/4885KDM4E 4857/4885MAPKAPK2 3713/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | EGFR 2/4885KDM4E 2238/4885MAPKAPK2 527/4885 |
| US-20250230166-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, HDAC11 | EGFR 3354/4885KDM4E 2674/4885MAPKAPK2 1161/4885 |
| US-20080027068-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | EGFR 257/4885KDM4E 4486/4885MAPKAPK2 2213/4885 |
| US-20080317839-A1 | AMINO ACID LIPIDS AND USES THEREOF | AADAT, AARS1, ABAT | EGFR 234/4885KDM4E 3447/4885MAPKAPK2 3295/4885 |
| US-20020010154-A1 | Compositions comprising cyclodextrin | FFAR4, FRG1, FGB | EGFR 568/4885KDM4E 1253/4885MAPKAPK2 4222/4885 |
| US-20060258642-A1 | Quinazoline derivatives for the treatment of tumours | TPD52L2, NQO2, H1-5 | EGFR 1723/4885KDM4E 1901/4885MAPKAPK2 3906/4885 |
| US-20100310535-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, CD44, NES | EGFR 1087/4885KDM4E 2378/4885MAPKAPK2 4786/4885 |
| US-12590084-B2 | Oxadiazole HDAC6 inhibitors and uses thereof | HDAC6, HDAC1, HDAC9 | EGFR 1297/4885KDM4E 1491/4885MAPKAPK2 669/4885 |
| US-20110130327-A1 | Multi-Arm Amines and Uses Thereof | SNRPE, SNRPA, ADAR | EGFR 141/4885KDM4E 1453/4885MAPKAPK2 3578/4885 |
| US-20100298559-A1 | OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST | C5, C9, CCNE1 | EGFR 1909/4885KDM4E 2758/4885MAPKAPK2 2961/4885 |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | EGFR 243/4885KDM4E 4435/4885MAPKAPK2 1568/4885 |
| US-20160058870-A1 | LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS | LNPEP, LPXN, SLC27A1 | EGFR 1869/4885KDM4E 4812/4885MAPKAPK2 4034/4885 |
| US-20260055090-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | HDAC6, HDAC1, CTTN | EGFR 645/4885KDM4E 3413/4885MAPKAPK2 996/4885 |
| US-20260102395-A1 | INHIBITING HISTONE DEACETYLASE 6 | HDAC6, HDAC1, HDAC8 | EGFR 2282/4885KDM4E 866/4885MAPKAPK2 2770/4885 |
| US-20100310536-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, CD44, NES | EGFR 1247/4885KDM4E 2378/4885MAPKAPK2 4796/4885 |
| US-20100240731-A1 | LIPOPEPTIDES FOR DELIVERY OF NUCLEIC ACIDS | LNPEP, LPXN, SLC27A1 | EGFR 1882/4885KDM4E 4784/4885MAPKAPK2 4127/4885 |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, MPL, IL1RN | EGFR 248/4885KDM4E 4616/4885MAPKAPK2 1982/4885 |
| US-20140051857-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | EGFR 242/4885KDM4E 4480/4885MAPKAPK2 2152/4885 |
| US-20100286390-A1 | PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS | P2RY1, P2RX7, P2RX1 | EGFR 2861/4885KDM4E 3762/4885MAPKAPK2 603/4885 |
| US-20100310537-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, CD44, NES | EGFR 1247/4885KDM4E 2378/4885MAPKAPK2 4796/4885 |
| US-20100112042-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | SLC27A2, LYPLA2, SLC47A2 | EGFR 2068/4885KDM4E 4573/4885MAPKAPK2 1540/4885 |
| US-20140308304-A1 | LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | NPC1L1, NPC1, CETP | EGFR 1466/4885KDM4E 3748/4885MAPKAPK2 3732/4885 |
| US-20080207960-A1 | Methods, compositions, and kits for post-hybridization processing of arrays | PARG, PUF60, TP53 | EGFR 2789/4885KDM4E 4204/4885MAPKAPK2 3890/4885 |
| US-20130012708-A1 | HETEROCYCLIC COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATORS | NR2C2, ROR1, NR0B2 | EGFR 242/4885KDM4E 4480/4885MAPKAPK2 2152/4885 |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | EGFR 649/4885KDM4E 4212/4885MAPKAPK2 1800/4885 |
| US-20040214841-A1 | Quinazoline derivatives for treatment of tumours | NQO2, TOP1, TPD52L2 | EGFR 1547/4885KDM4E 2520/4885MAPKAPK2 3573/4885 |
| US-20130039970-A1 | Processes and Compositions for Liposomal and Efficient Delivery of Gene Silencing Therapeutics | SLC27A2, LYPLA2, SLC27A1 | EGFR 2331/4885KDM4E 4127/4885MAPKAPK2 1549/4885 |
| US-20140037714-A1 | AMINO ACID LIPIDS AND USES THEREOF | AADAT, AARS1, ABAT | EGFR 234/4885KDM4E 3447/4885MAPKAPK2 3295/4885 |
| US-20090023939-A1 | ALPHA-SUBSTITUTED VINYLTIN COMPOUND | TST, CCNT1, TMT1A | EGFR 1817/4885KDM4E 1580/4885MAPKAPK2 4408/4885 |
| US-20090281317-A1 | 3-ETHYLIDENEHYDRAZINO SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | MPL, TEK, THPO | EGFR 200/4885KDM4E 4398/4885MAPKAPK2 1455/4885 |
| US-20050038050-A1 | Quinazoline derivatives for the treatment of t cell mediated diseases | CD4, HLA-DRB1, IFNG | EGFR 4734/4885KDM4E 1796/4885MAPKAPK2 3513/4885 |
| US-20100280042-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF TUMOURS | TPD52L2, NQO2, H1-5 | EGFR 1723/4885KDM4E 1901/4885MAPKAPK2 3906/4885 |
| US-20250250263-A1 | INHIBITING HISTONE DEACETYLASE 6 (HDAC6) | HDAC6, HDAC1, HDAC9 | EGFR 2951/4885KDM4E 1593/4885MAPKAPK2 954/4885 |
| US-20110177160-A1 | Amino acid lipids and uses thereof | AADAT, AARS1, ABAT | EGFR 234/4885KDM4E 3447/4885MAPKAPK2 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.